-
PUBLICATION
Drug efficacy study in NASH mouse model
2022.02.23
We would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) model. (Murakami et al., Cells., 2022).
-
PUBLICATION
Published papers with IPF model
2022.02.10
We would like to share with you some examples of studies that our clients have often asked us about using the IPF model.
-
UPDATE
Why is Chronic Kidney Disease so hard to research?
2022.01.27
Between 9 - 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, how can we develop more effective therapies for this underserved population?
-
UPDATE
What is proteinuria’s role in evaluating the progression of CKD?
2022.01.25
When discussing our mouse models for chronic kidney disease (CKD), we are often asked about proteinuria as a urinary marker of kidney damage. As an important marker used in clinical trials, it's also an important endpoint to look at in non-clinical research as well.
-
UPDATE
What is the relationship between NASH and Liver Cancer?
2022.01.18
You may know that liver cancer is one of the most prevalent cancers, but do you know about its relationship with nonalcoholic steatohepatitis (NASH), which is rapidly increasing as a liver disease?
-
UPCOMING EVENTS
SMC attend BIO Partnering at JPM Week!
2022.01.10
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering event next week from Monday, January 10th to Friday, January 14th.
-
UPDATE
2021.12.17
COVID-19 is a virus belonging to the beta-coronavirus class, similar to the virus that causes severe acute respiratory syndrome (SARS). It has been reported that fibrosis could begin to be observed several weeks after infection during the SARS epidemic.
-
NEWS RELEASE
2021.11.24
Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ mouse model.
-
UPCOMING EVENTS
SMC announces Presentation of New Data at the KDDW 2021
2021.10.27
We are pleased to announce the acceptance of our abstracts, “Molecular Pathogenesis of Non-Alcoholic Steatohepatitis (NASH) through the Dysregulation of Metabolic Organ Network in the NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet” and "RNA-Seq Analysis of Liver from NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet"—KDDW 2021, to be held from November 18 to 20, 2021.
-
PRESS RELEASES
STZ: Type 1 or Type 2 Diabetes?
2021.10.08
When discussing our unique NASH-HCC model STAM with clients, we are so often asked: What type of diabetes does the streptozotocin induce?
-
UPCOMING EVENTS
Reserve a non-clinical pharmacology consultation with us at BioPharm America!
2021.09.15
We are joining BioPharm America™ Digital, one of the most famous virtual biotech partnering and education events.
-
UPCOMING EVENTS
2021.09.07
We will be attending the annual 24th BioJapan from Wednesday, October 13th, 2021 – Friday, October 15th, 2021 (10/13 – 15, 2021) at the Pacifico Yokohama Convention Center!
